Q. Gu, R. Paulose-ram, V. Burt, and B. Kit, Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, NCHS Data Brief, issue.177, pp.1-8, 2003.

H. Ganga, H. Slim, and P. Thompson, A systematic review of statin-induced muscle problems in clinical trials, American Heart Journal, vol.168, issue.1, pp.6-15
DOI : 10.1016/j.ahj.2014.03.019

M. Law and A. Rudnicka, Statin Safety: A Systematic Review, The American Journal of Cardiology, vol.97, issue.8, pp.52-60, 2006.
DOI : 10.1016/j.amjcard.2005.12.010

D. Stewart, A. Mair, M. Wilson, P. Kardas, P. Lewek et al., Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments, Expert Opinion on Drug Safety, vol.16, issue.2, pp.203-216, 2017.
DOI : 10.1080/14740338.2017.1265503
URL : https://openair.rgu.ac.uk/bitstream/10059/2071/3/STEWART%202016%20Guidance%20to%20manage%20inappropriate%20polypharmacy.pdf

M. Thai, E. Reeve, S. Hilmer, K. Qi, S. Pearson et al., Prevalence of statin-drug interactions in older people: a systematic review, European Journal of Clinical Pharmacology, vol.32, issue.3, pp.513-534, 2016.
DOI : 10.1007/s40266-015-0302-9

S. Egger, R. Bravo, A. Hess, L. Schlienger, R. Krähenbühl et al., Age-Related Differences in the Prevalence of Potential Drug-Drug Interactions in Ambulatory Dyslipidaemic Patients Treated with Statins, Drugs & Aging, vol.26, issue.1, pp.429-469, 2007.
DOI : 10.2165/00002512-200724050-00006

. Interactions-médicamenteuses-ansm, Agence nationale de sécurité du médicament et des produits de santé [Internet] Available from: http://ansm.sante.fr/Dossiers/Interactions-medicamenteuses/Interactionsmedicamenteuses

V. Hoptimal, ]. Internet, and . Vidal-france, Available from: http://www.vidalfrance.com/solutions/solutions-professionnels/vidal-hoptimal/ 10, Thériaque [Internet]. [cited 2017 May 17]. Available from

G. Kongsholm, A. Nielsen, and P. Damkier, Drug interaction databases in medical literature: transparency of ownership, funding, classification algorithms, level of documentation, and staff qualifications. A systematic review, European Journal of Clinical Pharmacology, vol.13, issue.11, pp.1397-402, 2015.
DOI : 10.1186/2050-6511-13-7

D. Delamarre, G. Bouzille, K. Dalleau, D. Courtel, and M. Cuggia, Semantic integration of medication data into the EHOP Clinical Data Warehouse, Stud Health Technol Inform, vol.210, pp.702-708, 2015.

M. Hu and B. Tomlinson, Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin, Expert Opinion on Drug Metabolism & Toxicology, vol.5, issue.1, pp.51-65, 2014.
DOI : 10.2217/pgs.09.18

T. Hirota and I. Ieiri, Drug???drug interactions that interfere with statin metabolism, Expert Opinion on Drug Metabolism & Toxicology, vol.60, issue.6, pp.1435-1482, 2015.
DOI : 10.1093/ajh/6.11.375S

S. Bellosta and A. Corsini, Statin drug interactions and related adverse reactions, Expert Opinion on Drug Safety, vol.42, issue.1, pp.933-979
DOI : 10.1016/j.ejps.2011.09.009

. Drugbank, Available from: https

M. Patel, K. Taskar, and M. Zamek-gliszczynski, Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites, The Journal of Clinical Pharmacology, vol.65, issue.5, pp.23-39
DOI : 10.1097/QAI.0000000000000090

B. Wiggins, J. Saseen, R. Page, B. Reed, K. Sneed et al., Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation, vol.134, issue.21, pp.468-95, 2016.
DOI : 10.1161/CIR.0000000000000456

C. Campana, M. Regazzi, I. Buggia, and M. Molinaro, Clinically Significant Drug Interactions with Cyclosporin, Clinical Pharmacokinetics, vol.30, issue.2, pp.141-79, 1996.
DOI : 10.2165/00003088-199630020-00004

A. Kalliokoski and M. Niemi, Impact of OATP transporters on pharmacokinetics, British Journal of Pharmacology, vol.62, issue.2, pp.693-705, 2009.
DOI : 10.1111/j.1365-2125.2006.02686.x

J. Abarca, L. Colon, V. Wang, D. Malone, J. Murphy et al., Evaluation of the Performance of Drug-Drug Interaction Screening Software in Community and Hospital Pharmacies, Journal of Managed Care Pharmacy, vol.12, issue.5, pp.383-392, 2006.
DOI : 10.18553/jmcp.2006.12.5.383

G. Ramos, L. Guaraldo, A. Japiassú, and F. Bozza, Comparison of two databases to detect potential drug-drug interactions between prescriptions of HIV/AIDS patients in critical care, Journal of Clinical Pharmacy and Therapeutics, vol.27, issue.1, pp.63-70, 2015.
DOI : 10.1046/j.1365-2710.2002.00434.x

P. Fernández-de, M. Espinosa, D. Carrasco, M. , A. Romero et al., Potential drug???drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors, International Journal of Clinical Pharmacy, vol.71, issue.suppl, pp.1021-1028, 2015.
DOI : 10.1007/s00280-013-2162-5

J. Abarca, D. Malone, E. Armstrong, A. Grizzle, P. Hansten et al., Concordance of Severity Ratings Provided in Four Drug Interaction Compendia, Journal of the American Pharmacists Association, vol.44, issue.2, pp.136-177, 2003.
DOI : 10.1331/154434504773062582

L. Wang, M. Wong, J. Lightwood, and C. Cheng, Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening Programs, Annals of Pharmacotherapy, vol.61, issue.1, pp.28-34, 2010.
DOI : 10.1016/j.jaci.2005.10.031

P. Vonbach, A. Dubied, S. Krähenbühl, and J. Beer, Evaluation of frequently used drug interaction screening programs, Pharmacy World & Science, vol.44, issue.2, pp.367-74, 2008.
DOI : 10.1016/S1086-5802(16)31244-X

R. Scheife, L. Hines, R. Boyce, S. Chung, J. Momper et al., Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf, Feb, vol.38, issue.2, pp.197-206, 2015.

S. Phansalkar, A. Desai, D. Bell, E. Yoshida, J. Doole et al., High-priority drugdrug interactions for use in electronic health records, J Am Med Inform Assoc, 2012.

A. Vitry, Comparative assessment of four drug interaction compendia, British Journal of Clinical Pharmacology, vol.41, issue.6, pp.709-723, 2007.
DOI : 10.1331/154434504773062573

D. Food and . Administration, Guidance for industry: drug interaction studies?study design, data analysis, and implications for dosing and labeling recommendations: draft guidance. 2012. US Department of Health and Human Services Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/uc m292362.pdf. 35. Guideline on the investigation of drug interaction shttp, 2014.

S. Caccia, S. Garattini, L. Pasina, and A. Nobili, Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies, Drug Safety, vol.315, issue.6, pp.1017-1056, 2009.
DOI : 10.1136/bmj.315.7115.1096

J. Horn, P. Hansten, and L. Chan, Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother, pp.674-80, 2007.

E. Van-roon, S. Flikweert, M. Le-comte, P. Langendijk, W. Kwee-zuiderwijk et al., Clinical Relevance of Drug-Drug Interactions, Drug Safety, vol.53, issue.12, pp.1131-1140, 2005.
DOI : 10.2165/00002018-200528120-00007

P. Vonbach, A. Dubied, S. Krähenbühl, and J. Beer, Prevalence of drug???drug interactions at hospital entry and during hospital stay of patients in internal medicine, European Journal of Internal Medicine, vol.19, issue.6, pp.413-415, 2008.
DOI : 10.1016/j.ejim.2007.12.002